COVID-19 and Colorectal Cancer Get The Facts

Four actionable targets for metastatic colorectal cancer

In the past two years, findings from important clinical trials are shaping a new approach to treating different subgroups of patients with metastatic colorectal cancer (mCRC). Today, screening patients for biomarkers such as microsatellite instability status, BRAFV600E, HER2 and neurotrophic tyrosine receptor kinase (NTRK) is understood to be a fundamental step in developing a treatment approach that is best tailored to the patient.

But first, what is a cancer biomarker?

According to the World Health Organization, a cancer biomarker is “any substance, structure or process that can be measured in the body and influences or predicts the incidence of disease”. Biomarkers can help to measure the risk of developing cancer in a specific tissue, or can help to better understand the risk of cancer progression or potential response to therapy. Biomarker testing is being increasingly acknowledged as a crucial step towards more personalized, effective medicine.

Microsatellite instability

Microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) status are important colorectal cancer biomarkers that occur in about 5% of mCRC. MSI-H/dMMR occurs when a cell is unable to repair mistakes made during the cell division process, leading to accumulations of errors in sequences of DNA called microsatellites.

The KEYNOTE-177 study compared the immunotherapy drug pembrolizumab (Keytruda, Merck) with standard chemotherapy as initial treatment for patients with MSI-high mCRC, which typically has poor disease outcomes. Findings showed that pembrolizumab significantly improved progression-free survival (the time following treatment that the patient lives without their cancer getting worse) with a higher overall response rate and fewer side effects compared to chemotherapy.

BRAFV600E

BRAFV600E is another biomarker which, when present, leads to poor disease outcomes. BRAFV600E is a mutation that occurs in the BRAF gene, which, alongside other proteins such as EGFR or MEK, is involved in cell growth and division. Findings from the phase III BEACON CRC clinical trial found that dual and triple inhibition of BRAF-EGFR, or BRAF-EGFR-MEK with targeted therapy drugs resulted in better disease outcomes compared to standard chemotherapy among this subset of mCRC patients.

The ongoing ANCHOR study is investigating the effects of BRAF-EGFR inhibition as first-line therapy among patients with BRAFV600E-positive mCRC.

HER2 amplification

A small subset of patients with mCRC demonstrates HER2 amplification or overexpression, a gene that is also involved in metastatic breast cancer. The MyPathway trial examined the effectiveness of pertuzumab (Perjeta, Genentech) in combination with trastuzumab (Herceptin, Genentech) for HER2-positive mCRC. Results showed a promising response rate among patients who had been treated unsuccessfully with other therapies.

NTRK fusion

Patients with mCRC who test positive for the rare NTRK fusions now have several promising treatment options based on evidence from recent clinical trials. Larotrectinib (Vitrakvi, Bayer) and entrectinib (Rozlytrek, Genentech) are TRK inhibitors that have been approved for the treatment of mCRC patients with NTRK fusions, showing longer-lasting response rates compared to standard of care.

These exciting new therapies reinforce the importance of biomarker testing on patients to best tailor their treatment to their disease. For more information on biomarker testing, visit Colorectal Cancer Alliance’s Biomarkers 101 page.

Optimal sequencing strategies in metastatic colorectal cancer

Dr. Heinz-Josef Lenz, MD, discusses optimal sequencing strategies for [...]

READ MORE

ESMO Virtual Congress 2020: Colorectal cancer highlights

The European Society for Medical Oncology ESMO Virtual Congress 2020 t [...]

READ MORE

Welcoming Our Newest CCC Ambassador, Jesse Fishman!

Jesse Fishman is a 17-year-old hockey player, currently playing for the Ki [...]

READ MORE

Do young diabetes patients need early CRC screening?

12 August 2020 Recent findings from a Swedish cohort study found that p [...]

READ MORE

Cancer Recurrence amid COVID-19: Robin’s Story

It was the day of the lockdown. My family doctor called. “The colorectal c [...]

READ MORE

Never Too Young Survey Launch

Fill out the survey! The world was shocked late last week as we learned a [...]

READ MORE

Gut bacteria found to modulate response to cancer immunotherapy

Previous data have shown that certain species of intestinal bacteria not o [...]

READ MORE

Your Seasonal Guide to Cancer-Fighting Foods

As we transition into autumn, take a moment to appreciate the seasonal pro [...]

READ MORE

Psychosocial support for patients with cancer during COVID-19

The COVID-19 pandemic has presented countless new challenges in cancer car [...]

READ MORE

COVID-19 NEWSLETTER

The COVID-19 pandemic situation is constantly evolving. Canada is slowly r [...]

READ MORE

CRC with peritoneal metastases: CRS-HIPEC refinements

Results of several new studies provide important perspectives on the use o [...]

READ MORE

Patient Group Pathway Model to Accessing Cancer Clinical Trials and RWE Conference

Hold the Date! On behalf of Colorectal Cancer Canada (CCC), you are cordi [...]

READ MORE

Lynch Syndrome, Explained

What is Lynch Syndrome? Lynch syndrome is a genetically inherited conditi [...]

READ MORE

COVID-19 PATIENT SURVEY REPORT

Coronavirus has taken the world by storm since the beginning of 2020, and [...]

READ MORE

PUSH FOR YOUR TUSH VIRTUAL EVENT 2020

To ensure the health and safety of our participants, volunteers, staff and [...]

READ MORE

Gastrointestinal Highlights from last month’s ASCO 2020 Meeting

The American Society of Clinical Oncology (ASCO) held its annual meeting a [...]

READ MORE

How is colorectal cancer care changing in the era of COVID-19?

In just a few months, coronavirus (COVID-19) has transformed our lives. De [...]

READ MORE

Meatless for CRC prevention

It has been known for millennia that what we eat can be powerful medicine [...]

READ MORE

Immunotherapy treatment proves to be superior to chemotherapy for a specific subset of patients with mCRC

The last few decades have seen important advances in colorectal cancer tre [...]

READ MORE

Push For Your Tush volunteers spread the word

Co-leads of Push For Your Tush Ottawa share their connection to the cause [...]

READ MORE

2,700 VISITORS PASS THROUGH GIANT COLON TOUR AT THE SHERBROOKE HALF MARATHON

The Centre de recherche of the Centre hospitalier universitaire de Sherbro [...]

READ MORE

Colorectal cancer screening in Ontario is changing to the FIT

On June 24, 2019, colorectal cancer screening in Ontario is changing to th [...]

READ MORE

Remembering the “Father of Heredity Cancer” Dr. Henry Lynch

Today we remember Dr. Henry Lynch, esteemed researcher and father of hered [...]

READ MORE

Kicking cancer’s ass on the golf course

On Tuesday, July 16, Colorectal Cancer Canada (CCC) held our third annual [...]

READ MORE

Increasing rates of colon & rectal cancers in young people

Researchers with the World Health Organization confirm increased rates of [...]

READ MORE

CCC attends Early Age Onset Colorectal Cancer Summit in New York City

Last Thursday and Friday, Morgan Kennedy, CCC’s Never Too Young Program Ma [...]

READ MORE

Publication: Clinically meaningful survival benefit in refractory mCRC

Colorectal Cancer Canada (CCC) is proud to announce the publication of the [...]

READ MORE

Giant Colon visits University of Montreal Hospital Centre

Today, the Giant Colon Tour stopped at the University of Montreal Hospital [...]

READ MORE

CCC’s PUSH FOR YOUR TUSH SPARKS PARTNERSHIP WITH THE TORONTO PROFESSIONAL FIRE FIGHTERS ASSOCIATION

Most people do not know that cancer is the number one cause of death among [...]

READ MORE

March is Colorectal Cancer Awareness Month

March is Colorectal Cancer Awareness Month! Colorectal cancer may touch yo [...]

READ MORE

Sponsors